U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C12H24N2O4
Molecular Weight 260.33
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CARISOPRODOL

SMILES

CCCC(C)(COC(N)=O)COC(=O)NC(C)C

InChI

InChIKey=OFZCIYFFPZCNJE-UHFFFAOYSA-N
InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)

HIDE SMILES / InChI
Molecular Formula C12H24N2O4
Molecular Weight 260.33
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including: http://www.ncbi.nlm.nih.gov/pubmed/22318620, http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c9184c0-7a2e-11df-8c8d-0002a5d5c51b

A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. Carisoprodol is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Most common adverse reactions (incidence > 2%) are drowsiness, dizziness, and headache. Carisoprodol might be mixtured with Aspirin and Codeine Phosphate. Studies indicating increased risk of abuse or addiction led to withdrawal of the drug from the market in Norway and other EU countries in 2008.

CNS Activity

Originator

Wallace Laboratories
3
Curator's Comment: Carisoprodol was developed in the 1950s by Dr. Frank M. Berger at Wallace laboratories on the basis of meprobamate.

Approval Year

1959
138
Targets

Targets

Primary TargetPharmacologyConditionPotency
Positive Allosteric Modulator
179
 142.0 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8429
SOMA

Approved Use

SOMA is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. SOMA should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration

Launch Date

1959
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.2 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/011792s048lbl.pdf
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.8 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011792s050lbl.pdf
350 mg single, oral
dose: 350 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
13.3 μM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7974621
700 mg single, oral
dose: 700 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.5 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/011792s048lbl.pdf
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011792s050lbl.pdf
350 mg single, oral
dose: 350 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.7 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/011792s048lbl.pdf
250 mg single, oral
dose: 250 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011792s050lbl.pdf
350 mg single, oral
dose: 350 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
99 min
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7974621
700 mg single, oral
dose: 700 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
46%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7974621
700 mg single, oral
dose: 700 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CARISOPRODOL serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 548
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 548
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Disc. AE: Dizziness, Headache...
AEs leading to
discontinuation/dose reduction:
Dizziness (0.5%)
Headache (0.5%)
Diarrhea (0.2%)
Stomach discomfort (0.2%)
Upper abdominal pain (0.2%)
Intervertebral disc protrusion (0.2%)
Pain in extremity (0.2%)
Abdominal distension (0.2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Disc. AE: Dizziness, Headache...
AEs leading to
discontinuation/dose reduction:
Dizziness (0.7%)
Headache (0.4%)
Stomach discomfort (0.7%)
Upper abdominal pain (0.7%)
Somnolence (0.7%)
Nausea (0.4%)
Rash (0.4%)
Nephrolithiasis (0.4%)
Intervertebral disc protrusion (0.4%)
Fatigue (0.4%)
Disorientation (0.4%)
Paraesthesia (0.4%)
Skin papilloma (0.4%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
2100 mg 1 times / day steady, oral
Highest studied dose
Dose: 2100 mg, 1 times / day
Route: oral
Route: steady
Dose: 2100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1998178
unhealthy, adult
n = 9
Health Status: unhealthy
Age Group: adult
Sex: M
Population Size: 9
Sources:
https://pubmed.ncbi.nlm.nih.gov/1998178
Sources:
https://pubmed.ncbi.nlm.nih.gov/1998178
AEs

AEs

AESignificanceDosePopulation
Abdominal distension 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 548
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 548
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Diarrhea 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 548
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 548
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Intervertebral disc protrusion 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 548
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 548
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Pain in extremity 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 548
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 548
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Stomach discomfort 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 548
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 548
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Upper abdominal pain 0.2%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 548
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 548
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Dizziness 0.5%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 548
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 548
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Headache 0.5%
Disc. AE
250 mg 3 times / day steady, oral
Recommended
Dose: 250 mg, 3 times / day
Route: oral
Route: steady
Dose: 250 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 548
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 548
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Disorientation 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Fatigue 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Headache 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Intervertebral disc protrusion 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Nausea 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Nephrolithiasis 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Paraesthesia 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Rash 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Skin papilloma 0.4%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Dizziness 0.7%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Somnolence 0.7%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Stomach discomfort 0.7%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Upper abdominal pain 0.7%
Disc. AE
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
unhealthy, 41 years
n = 279
Health Status: unhealthy
Condition: acute, mechanical, lower back pain
Age Group: 41 years
Sex: M+F
Population Size: 279
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf
Page: 6
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587

substrate
1737
inhibitor
1852

substrate
1217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2C8
911
CYP2C19
991

CYP1A2
1054
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2C8
965
 weak
CYP2D6
1891
 weak
CYP3A4
1925
 weak
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2C19
991
 major
CYP1A2
1054
 yes
CYP2D6
1217
 yes
CYP3A4
1737
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:3419
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3419
ChemicalBook
CB0215440
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0215440
eMolecules
536553
https://www.emolecules.com/cgi-bin/more?vid=536553
PubMed

PubMed

TitleDatePubMed
WHO Expert Committee on Drug Dependence. Thirty-second report.
2001
Transfer of carisoprodol to breast milk.
2001 Jun
National All Schedules Prescription Electronic Reporting Act (NASPER): balancing substance abuse and medical necessity.
2002 Jul
Carisoprodol: an unrecognized drug of abuse.
2002 Mar
Somatic dysfunction during carisoprodol cessation: evidence for a carisoprodol withdrawal syndrome.
2003 Feb
Possible dangerous interaction of oxycontin and carisoprodol.
2003 Jun 1
Prescription of nonsteroidal anti-inflammatory drugs and muscle relaxants for back pain in the United States.
2004 Dec 1
Validated semiquantitative/quantitative screening of 51 drugs in whole blood as silylated derivatives by gas chromatography-selected ion monitoring mass spectrometry and gas chromatography electron capture detection.
2004 Jul 5
A randomized clinical trial comparing chiropractic adjustments to muscle relaxants for subacute low back pain.
2004 Jul-Aug
Identifying controlled substance patterns of utilization requiring evaluation using administrative claims data.
2004 Nov
Stimulant and relaxant drugs combined with stimulant and relaxant information: a study of active placebo.
2004 Nov
Recent trends of drug abuse and drug-associated deaths in Korea.
2004 Oct
Simultaneous determination of carisoprodol and meprobamate in human hair using solid-phase extraction and gas chromatography/mass spectrometry of the trimethylsilyl derivatives.
2005
Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs.
2005 Sep-Oct
A one-step and sensitive GC-MS assay for meprobamate determination in emergency situations.
2006 Jun
Carisoprodol abuse in Texas, 1998-2003.
2006 Mar
Botulinum toxin type A injection for management of upper limb spasticity in children with cerebral palsy: a literature review.
2006 Oct 31
Changing patterns of drug and alcohol use in fatally injured drivers in Washington State.
2006 Sep
Drug screening of preserved oral fluid by liquid chromatography-tandem mass spectrometry.
2007 Feb
The risk of traffic accidents after prescriptions of carisoprodol.
2007 Sep
Carisoprodol intoxications: a retrospective study of forensic autopsy material from 1992-2003.
2007 Sep
Acute intoxications with carisoprodol.
2008 Apr
Reliability of Ashworth and Modified Ashworth scales in children with spastic cerebral palsy.
2008 Apr 10
[Somadril will be recalled June 1, 2008].
2008 Apr 2-8
Is it time for carisoprodol to become a controlled substance at the federal level?
2008 Feb
Muscle and reflex changes with varying joint angle in hemiparetic stroke.
2008 Feb 27
Carisoprodol-induced amnestic state.
2008 Jan
Carisoprodol withdrawal syndrome misdiagnosed as a psychotic disorder.
2008 Jul-Sep
Carisoprodol should be taken off the market.
2008 Oct
Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology.
2009
A multi-drug intoxication fatality involving Xyrem (GHB).
2009 Mar
[Prescription shopping of addictive drugs in Norway].
2009 Mar 12
Prescription pattern of codeine for non-malignant pain: a pharmacoepidemiological study from the Norwegian Prescription Database.
2009 May
Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies.
2009 May
Introduction of low dose transdermal buprenorphine -- did it influence use of potentially addictive drugs in chronic non-malignant pain patients?
2009 Oct
Drugs associated with more suicidal ideations are also associated with more suicide attempts.
2009 Oct 2
Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions.
2010 Apr 7
Carisoprodol legal status and patterns of abuse.
2010 Dec
Rapid and sensitive LC-MS/MS method for determination of felbamate in mouse plasma and tissues and human plasma.
2010 Dec 15
Pharmacogenetics and forensic toxicology.
2010 Dec 15
Randomized, double-blind trial of carisoprodol 250 mg compared with placebo and carisoprodol 350 mg for the treatment of low back spasm.
2010 Jan
INCITE: A randomised trial comparing constraint induced movement therapy and bimanual training in children with congenital hemiplegia.
2010 Jan 12
Trace determination of pharmaceuticals and other wastewater-derived micropollutants by solid phase extraction and gas chromatography/mass spectrometry.
2010 Jan 22
Pharmaceutical formulation facilities as sources of opioids and other pharmaceuticals to wastewater treatment plant effluents.
2010 Jul 1
Observations of medication compliance by measurement of urinary drug concentrations in a pain management population.
2010 Jul-Aug
Carisoprodol: abuse potential and withdrawal syndrome.
2010 Mar
Comparison of drug concentrations in blood and oral fluid collected with the Intercept sampling device.
2010 May
Screening and quantitative determination of twelve acidic and neutral pharmaceuticals in whole blood by liquid-liquid extraction and liquid chromatography-tandem mass spectrometry.
2010 Sep
Patents

Patents

JP2011520977A
49
JPH05220234A
1
JPS62218825A
1
JPS62288550A
1

Sample Use Guides

In Vivo Use Guide
250 mg to 350 mg three times a day and at bedtime
Route of Administration: Oral
In Vitro Use Guide
HEK293 cells were transiently transfected with human alpha1beta2 and alpha1beta2gamma2 receptors. Whole-cell patch clamp electrophysiology was used to assess carisoprodol-activated Cl- current. EC50 value for carisoprodol was 142 ± 13 uM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:04:37 GMT 2023
Edited
by admin
on Fri Dec 15 15:04:37 GMT 2023
Record UNII
21925K482H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CARISOPRODOL
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
INN  
Official Name English
(±)-2-METHYL-2-PROPYL-1,3-PROPANEDIOL CARBAMATE ISOPROPYLCARBAMATE
Systematic Name English
CARISOPRODOL [HSDB]
Common Name English
CARISOPRODOL COMPONENT OF CARISOPRODOL COMPOUND
Common Name English
CARISOPRODOL [USP MONOGRAPH]
Common Name English
NSC-172124
Code English
CARISOPRODOL [MI]
Common Name English
CARISOPRODOL [EP IMPURITY]
Common Name English
CARISOPRODOL [JAN]
Common Name English
carisoprodol [INN]
Common Name English
SOMA
Brand Name English
Carisoprodol [WHO-DD]
Common Name English
RELA
Brand Name English
CARISOPRODOL CIV
USP-RS  
Common Name English
CARISOPRODOL COMPONENT OF SOMA COMPOUND
Common Name English
SOMA COMPOUND COMPONENT CARISOPRODOL
Common Name English
CARISOPRODOL [VANDF]
Common Name English
CARISOPRODOL [ORANGE BOOK]
Common Name English
CARISOPRODOL CIV [USP-RS]
Common Name English
CARISOPRODOL COMPOUND COMPONENT CARISOPRODOL
Common Name English
CARISOPRODOL [MART.]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175737
Created by admin on Fri Dec 15 15:04:38 GMT 2023 , Edited by admin on Fri Dec 15 15:04:38 GMT 2023
LIVERTOX NBK548829
Created by admin on Fri Dec 15 15:04:38 GMT 2023 , Edited by admin on Fri Dec 15 15:04:38 GMT 2023
WHO-ATC M03BA72
Created by admin on Fri Dec 15 15:04:37 GMT 2023 , Edited by admin on Fri Dec 15 15:04:37 GMT 2023
WHO-VATC QM03BA72
Created by admin on Fri Dec 15 15:04:38 GMT 2023 , Edited by admin on Fri Dec 15 15:04:38 GMT 2023
WHO-VATC QM03BA52
Created by admin on Fri Dec 15 15:04:38 GMT 2023 , Edited by admin on Fri Dec 15 15:04:38 GMT 2023
WHO-ATC M03BA02
Created by admin on Fri Dec 15 15:04:37 GMT 2023 , Edited by admin on Fri Dec 15 15:04:37 GMT 2023
NCI_THESAURUS C29696
Created by admin on Fri Dec 15 15:04:38 GMT 2023 , Edited by admin on Fri Dec 15 15:04:38 GMT 2023
WHO-VATC QM03BA02
Created by admin on Fri Dec 15 15:04:38 GMT 2023 , Edited by admin on Fri Dec 15 15:04:38 GMT 2023
DEA NO. 8192
Created by admin on Fri Dec 15 15:04:37 GMT 2023 , Edited by admin on Fri Dec 15 15:04:37 GMT 2023
WHO-ATC M03BA52
Created by admin on Fri Dec 15 15:04:37 GMT 2023 , Edited by admin on Fri Dec 15 15:04:37 GMT 2023
NDF-RT N0000175730
Created by admin on Fri Dec 15 15:04:38 GMT 2023 , Edited by admin on Fri Dec 15 15:04:38 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C28904
Created by admin on Fri Dec 15 15:04:38 GMT 2023 , Edited by admin on Fri Dec 15 15:04:38 GMT 2023
PRIMARY
MESH
D002328
Created by admin on Fri Dec 15 15:04:38 GMT 2023 , Edited by admin on Fri Dec 15 15:04:38 GMT 2023
PRIMARY
SMS_ID
100000084595
Created by admin on Fri Dec 15 15:04:38 GMT 2023 , Edited by admin on Fri Dec 15 15:04:38 GMT 2023
PRIMARY
RS_ITEM_NUM
1096600
Created by admin on Fri Dec 15 15:04:38 GMT 2023 , Edited by admin on Fri Dec 15 15:04:38 GMT 2023
PRIMARY
WIKIPEDIA
CARISOPRODOL
Created by admin on Fri Dec 15 15:04:38 GMT 2023 , Edited by admin on Fri Dec 15 15:04:38 GMT 2023
PRIMARY
LACTMED
Carisoprodol
Created by admin on Fri Dec 15 15:04:38 GMT 2023 , Edited by admin on Fri Dec 15 15:04:38 GMT 2023
PRIMARY
FDA UNII
21925K482H
Created by admin on Fri Dec 15 15:04:37 GMT 2023 , Edited by admin on Fri Dec 15 15:04:37 GMT 2023
PRIMARY
DAILYMED
21925K482H
Created by admin on Fri Dec 15 15:04:37 GMT 2023 , Edited by admin on Fri Dec 15 15:04:37 GMT 2023
PRIMARY
CHEBI
3419
Created by admin on Fri Dec 15 15:04:37 GMT 2023 , Edited by admin on Fri Dec 15 15:04:37 GMT 2023
PRIMARY
IUPHAR
7610
Created by admin on Fri Dec 15 15:04:38 GMT 2023 , Edited by admin on Fri Dec 15 15:04:38 GMT 2023
PRIMARY
HSDB
3021
Created by admin on Fri Dec 15 15:04:37 GMT 2023 , Edited by admin on Fri Dec 15 15:04:37 GMT 2023
PRIMARY
DRUG BANK
DB00395
Created by admin on Fri Dec 15 15:04:37 GMT 2023 , Edited by admin on Fri Dec 15 15:04:37 GMT 2023
PRIMARY
EPA CompTox
DTXSID8024733
Created by admin on Fri Dec 15 15:04:37 GMT 2023 , Edited by admin on Fri Dec 15 15:04:37 GMT 2023
PRIMARY
PUBCHEM
2576
Created by admin on Fri Dec 15 15:04:38 GMT 2023 , Edited by admin on Fri Dec 15 15:04:38 GMT 2023
PRIMARY
NSC
172124
Created by admin on Fri Dec 15 15:04:38 GMT 2023 , Edited by admin on Fri Dec 15 15:04:38 GMT 2023
PRIMARY
CAS
78-44-4
Created by admin on Fri Dec 15 15:04:37 GMT 2023 , Edited by admin on Fri Dec 15 15:04:37 GMT 2023
PRIMARY
DRUG CENTRAL
509
Created by admin on Fri Dec 15 15:04:37 GMT 2023 , Edited by admin on Fri Dec 15 15:04:37 GMT 2023
PRIMARY
EVMPD
SUB06631MIG
Created by admin on Fri Dec 15 15:04:37 GMT 2023 , Edited by admin on Fri Dec 15 15:04:37 GMT 2023
PRIMARY
ECHA (EC/EINECS)
201-118-7
Created by admin on Fri Dec 15 15:04:37 GMT 2023 , Edited by admin on Fri Dec 15 15:04:37 GMT 2023
PRIMARY
MERCK INDEX
m3112
Created by admin on Fri Dec 15 15:04:38 GMT 2023 , Edited by admin on Fri Dec 15 15:04:38 GMT 2023
PRIMARY Merck Index
RXCUI
2101
Created by admin on Fri Dec 15 15:04:38 GMT 2023 , Edited by admin on Fri Dec 15 15:04:38 GMT 2023
PRIMARY RxNorm
INN
902
Created by admin on Fri Dec 15 15:04:37 GMT 2023 , Edited by admin on Fri Dec 15 15:04:37 GMT 2023
PRIMARY
ChEMBL
CHEMBL1233
Created by admin on Fri Dec 15 15:04:37 GMT 2023 , Edited by admin on Fri Dec 15 15:04:37 GMT 2023
PRIMARY
Related Record Type Details
Structure of CARISOPRODOL
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Structure of CARISOPRODOL, (R)-
ENANTIOMER -> RACEMATE
Structure of CARISOPRODOL, (S)-
ENANTIOMER -> RACEMATE
Structure of CARISOPRODOL
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Related Record Type Details
Structure of 2-HYDROXYMETHYL-2-METHYLPENTYL ISOPROPYLCARBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 5-METHYL-5-PROPYL-1,3-DIOXAN-2-ONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
Structure of 2-HYDROXYMETHYL-2-METHYLPENTYL ISOPROPYLCARBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
Structure of 2-(HYDROXYMETHYL)-2-METHYLPENTYL CARBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
Structure of 2-(HYDROXYMETHYL)-2-METHYLPENTYL CARBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of MEPROBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of CARISOPRODOL
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966